Drugs /

temozolomide

Back to Drugs List

Overview

Generic Name(s):
temozolomide
Trade Name(s):
Methazolastone and Temodar
NCI Definition [1]:
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)

Clinical Trials

View Clinical Trials for temozolomide

Temozolomide has been investigated in 128 clinical trials, of which 112 are open and 16 are closed. Of the trials investigating temozolomide, 5 are early phase 1 (5 open), 36 are phase 1 (32 open), 21 are phase 1/phase 2 (18 open), 50 are phase 2 (43 open), 5 are phase 2/phase 3 (4 open), 8 are phase 3 (7 open), and 3 are no phase specified (3 open).

MGMT Promoter Methylation Positive, MGMT Promoter Methylation Negative, and del(1)(p10) are the most frequent biomarker inclusion criteria for temozolomide clinical trials.

Glioblastoma, gliosarcoma, and malignant solid tumor are the most common diseases being investigated in temozolomide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Temozolomide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Temozolomide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating temozolomide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
42084, Methazolastone, Temodar, m & b 39831, sch 52365, tmz, ccrg-81045, m and b 39831, temozolomid, m&b 39831, m & b 39831, temozolomide, 362856, temomedac, 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3h)-one, ccrg 81045, sch 52365, m&b-39831, 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, témozolomide, 85622-93-1, temodal, 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3h)-one, temozolomidum, imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3h)-one, sch52365, temozolomide (product), mb 39831, methazolastone, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, rp-46161, temozolomide [chemical/ingredient], temozolomide (substance), imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, temozolodida, temozolomide, temcad, temozolomida, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C1244
SNOMED ID [1]:
F-61BE4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.